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Microbiological and clinical effects 
of probiotics and antibiotics on 
nonsurgical treatment of chronic 
periodontitis: a randomized placebo-
controlled trial with 9-month follow-up
Objective: The aim of this double-blind, placebo-controlled and parallel-
arm randomized clinical trial was to evaluate the effects of Lactobacillus 
rhamnosus SP1-containing probiotic sachet and azithromycin tablets as an 
adjunct to nonsurgical therapy in clinical parameters and in presence and 
levels of Tannerella forsythia, Porphyromonas gingivalis and Aggregatibacter 
actinomycetemcomitans. Material and Methods: Forty-seven systemically 
healthy volunteers with chronic periodontitis were recruited and monitored 
clinically and microbiologically at baseline for 3, 6 and 9 months after 
therapy. Subgingival plaque samples were collected from four periodontal 
sites with clinical attachment level ≥1 mm, probing pocket depth ≥4 mm and 
bleeding on probing, one site in each quadrant. Samples were cultivated and 
processed using the PCR technique.  Patients received nonsurgical therapy 
including scaling and root planing (SRP) and were randomly assigned to a 
probiotic (n=16), antibiotic (n=16) or placebo (n=15) group. L. rhamnosus 
SP1 was taken once a day for 3 months. Azithromycin 500mg was taken 
once a day for 5 days.  Results: All groups showed improvements in clinical 
and microbiological parameters at all time points evaluated. Probiotic and 
antibiotic groups showed greater reductions in cultivable microbiota compared 
with baseline. The placebo group showed greater reduction in number of 
subjects with P. gingivalis compared with baseline. However, there were no 
significant differences between groups. Conclusions: The adjunctive use of 
L. rhamnosus SP1 sachets and azithromycin during initial therapy resulted 
in similar clinical and microbiological improvements compared with the 
placebo group.
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Introduction
Chronic periodontitis is an inflammatory disease, 
produced in response to periodontopathogens in the 
biofilm of the subgingival plaque, affecting tissues 
supporting the teeth. The prevalence of this disease 
is close to 90% worldwide. In Chile, the destruction 
of periodontal tissues affects the majority of the adult 
population. The loss of clinical attachment higher 
than 3 mm in at least one site was of 93.4% for the 
population aging 35-44 years and of 97.5% for the 
group aging 65-74 years. When the severity of clinical 
attachment loss increased to 5 mm or more in at least 
one site, the percentage of the population affected was 
58.3% and 81.4%, respectively6. 
The etiology of this disease has been considered 
as polymicrobial, in which specific bacteria in 
the community have been associated with the 
development of the disease after the host defense 
response to the noxa. Evidence shows that the total 
bacterial load varies in healthy sites when compared 
with unhealthy sites1. Members of the red complex, 
such as Porphyromonas gingivalis and Tannerella 
forsythia described by Socransky, et al23(1998), 
are considered as the most pathogenic microbial 
components at present. The bacteria of the red 
complex present a similar prevalence in patients 
with different forms of periodontitis23. Likewise, 
Aggregatibacter actinomycetemcomitans is associated 
with periodontal disease, but it does not belong to the 
red complex.
In Chile, the prevalence of P. gingivalis, A. 
actinomycetemcomitans and T. forsythia in adults with 
chronic periodontitis was higher than 75%, 20% and 
15% respectively5. In this context, periodontal therapy 
is focused on the control of the associated microbiota, 
removing or reducing the bacterial load of the 
periodontopathogens associated with the subgingival 
biofilm. The gold standard in periodontal treatment is 
formed by scaling and root planing4. Systemic antibiotic 
therapy is indicated to control deep periodontal 
pockets, difficult to access and with microbial invasion 
at epithelial level, with tissue destruction and disease 
progressing over time. The recolonization of other 
oral sites by periodontopathogens accounts for the 
failure of conventional therapy. Nevertheless, in Chile, 
there are no studies providing information about the 
response of the native microbiota to the systemic use 
of antibiotics. Therefore, it is important to consider 
the microbial resistance observed for the use of these 
antibacterial agents17. 
Given the background in the literature, the 
selection of bacterial species resistant to the 
antibacterial treatment has been considered a global 
problem after the excessive use of these drugs. This 
leads to the search for new tools for the control 
of infectious diseases8. The use of probiotics has 
become more common in recent years. They are food 
supplements with microbial elements that have a 
physiologic effect on the organism that receives them. 
The effect of the use of probiotics in the treatment of 
chronic periodontitis had been studied13,15,16,22,26,27,29. 
Lactobacillus constitutes the most common bacterial 
genus used as a probiotic. In vitro studies have 
shown that oral strains of Lactobacillus, including 
Lactobacillus rhamnosus, display a strong inhibitory 
effect against the cariogenic species as well as against 
the Gram-negative periodontal pathogens25. Thus, 
the objective of our study was to evaluate the effects 
of Lactobacillus rhamnosus SP1 containing probiotic 
sachet and azithromycin tablets as an adjunct to 
nonsurgical therapy in clinical and microbiological 
parameters of chronic periodontitis. 
Material and methods
Participant population and inclusion and 
exclusion clinical criteria 
This study was carried out between June 2014 and 
August 2016. It is a double-blind, placebo-controlled 
and parallel-arm randomized clinical trial and it was 
conducted in accordance with the Helsinki Declaration 
of 1975, as revised in 2013. This clinical trial was 
approved by the local Research Ethics Committee of 
the Faculty of Dentistry, University of Chile (Decision 
no.: 2012/ 08). The protocol of the study was explained 
to all patients, who signed an informed consent form 
after explanation of the purpose, nature, risks and 
benefits of participating in this study (identification no. 
NCT02839408; http://www.clinicaltrials.gov). 
Individuals in search of periodontal care or patients 
referred to the Diagnosis Center of the Faculty of 
Dentistry, University of Chile, for periodontal care 
were screened for the study. Ninety-six volunteers 
were initially examined, of which we included 47 
in this study. Inclusion criteria were: healthy, non-
institutionalized male or female subjects, at least 35 
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years of age, presence of a minimum of 14 natural 
teeth, excluding third molars, presence of at least 10 
posterior teeth, previously untreated for periodontitis. 
Exclusion criteria were: suffering any systemic 
illness, pregnant and breastfeeding women, having 
received any periodontal treatment before the time of 
examination, having received antibiotics or non-steroid 
anti-inflammatory therapy in the 6-month period prior 
to the study. Chronic periodontitis was determined as 
follows: presence of at least five teeth with periodontal 
sites with pocket probing depth (PPD) ≥ 4mm and 
clinical attachment loss (CAL) ≥1 mm, 20% bleeding 
on probing (BOP) and extensive radiographically 
determined bone loss28.
Experimental design: clinical trial
Sample size calculation, based on a study previously 
published16, was made for the primary outcome 
variable (CAL), considering a standard deviation of 1 
mm and a difference between the groups of 1 mm. 
According to the calculation, 14 patients were needed 
in each group to provide 80% power with an α of 0.05. 
After baseline examinations, all patients were given 
proper oral hygiene instructions, using standardized 
manual toothbrush. Scaling and root planing per 
quadrant was performed with one-week intervals in 4-6 
sessions (by Paola Carvajal and Claudia Godoy). SRP 
was performed using an ultrasonic scaler (Cavitron, 
Dentsply, York, PA, U.S.A) and hand instruments 
(Hu Friedy Mfg. Co. Inc., Chicago, IL, U.S.A.). The 
study coordinator (Jorge Gamonal) randomized the 
participants over the three treatment groups: placebo 
(SRP + placebo), probiotic (SRP + probiotic) or antibiotic 
(SRP + antibiotic) group. According to gender, age, 
and smoking status, eligible individuals were randomly 
allocated to groups after the basal examination, using 
a computer-generated randomization table (Jorge 
Gamonal). Allocation concealment was prepared using 
sequentially numbered, opaque sealed envelopes. 
The probiotic group patients received Lactobacillus 
rhamnosus SP1 [(2x107colony forming units (CFU)/
day)] (Macrofood S.A., Santiago de Chile, Chile) for 3 
months. The dose was one sachet taken orally daily. 
The sachets presented to the patients were identical. 
Individuals were instructed to dissolve 1 sachet in 
water (150 mL) and ingest it once a day after brushing 
their teeth. Also, probiotic group patients received 
placebo with identical taste and appearance than 
antibiotic capsules. The antibiotic group patients took 
azithromycin 500 mg q.d, for 5 days and a probiotic 
placebo with identical taste, texture and appearance to 
the probiotic sachet. Placebo group patients received 
placebo from the manufacturer of identical taste, 
texture, and appearance to the probiotic sachet and 
antibiotic capsule. The patients started taking the 
probiotic, antibiotic or placebo after the last session 
of SRP. Every 3 months, they received periodontal 
supportive therapy (by Paola Carvajal and Claudia 
Godoy), with monitoring of individual compliance, 
medical history and diet throughout the study period. 
Patients, examiner and dentists who performed 
periodontal treatment were blinded to the study group 
assignment except for the study coordinator (Jorge 
Gamonal). The designation of the different groups was 
only revealed after study completion. 
The study coordinator handed out the study 
materials.
Clinical examination 
Periodontal clinical examination consisted of 
full-mouth PPD, dichotomous measurements of 
supragingival plaque accumulation, and BOP at the 
base of the crevice, measured at six sites per tooth. 
CAL was determined using the distance from the 
cement-enamel junction (CEJ) to the free gingival 
margin (FGM) and the distance from the FGM to the 
bottom of the pocket/sulcus. All examinations were 
performed using a first generation manual periodontal 
probe (UNC-15, Hu Friedy Mfg. Co. Inc., Chicago, IL, 
U.S.A.) by one calibrated examiner (Alicia Morales) 
(intra-class correlation coefficient of 0.80 for CAL).
Clinical examination was recorded at baseline 3, 6 
and 9 months after therapy. 
Subgingival plaque samples
Subgingival plaque samples were collected from 
four periodontal sites with clinical attachment level 
≥ 1mm, probing pocket depth ≥ 4mm and bleeding 
on probing, one site in each quadrant. After isolating 
the area with cotton rolls and gently air-drying it, 
supragingival deposits were carefully removed with 
curettes (Hu Friedy Mfg. Co. Inc., Chicago, IL, U.S.A). 
Two standardized no. 30 sterile paper points (Johnson 
& Johnson, Tokyo, Japan) were inserted into the 
deepest part of the periodontal pocket for 20 seconds 
in order to obtain subgingival microbial samples. 
Each sample was deposited in a vial containing 1 ml 
of cold sterilized pre-reduced transport fluid (RTF) 
without EDTA. Vials with samples were transported at 
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4°C to the Microbiological Laboratory of the Faculty 
of Dentistry, University of Chile, and processed 
immediately.
Subgingival samples were collected at baseline 3, 
6 and 9 months after therapy by one examiner (Jorge 
Gamonal).
Microbiological procedures
Microbiological procedures were performed by one 
expert (Nora Silva).
Subgingival plaque samples were dispersed by 
mixing for 45 seconds followed by a 10-fold serial 
dilution of the bacterial suspension in RTF, using PBS. 
Procedures to detect and quantify P. gingivalis and 
T. forsythia were: Aliquots of 100 μL of the appropriate 
dilution (10-2 and 10-3) were plated on nonselective 
blood- agar, hemin- menadione medium. Plates were 
anaerobically incubated at 35°C for 14 days in a jar 
containing gas generator envelopes for the production 
of an anaerobic atmosphere (Anaerogen. Oxoid 
Limited, Wade Road, Basingstoke, Hampshire, U.K.). 
Procedures  to  de tec t  and  quant i fy  A . 
actinomycetemcomitans were: Aliquots of 100 μL 
of the appropriate dilution (undiluted and 10-1) were 
plated on selective TSBV medium (trypticase, 10% 
horse serum, bacitracin, and vancomycin). Plates were 
incubated at 37°C for 2 to 3 days in CO2 candle jars.
Bacteria were primarily identified by colony 
morphology under a stereoscopic microscope (Stmi 
2000-C, Zeiss, Jena, Germany), pigment production 
and Gram stain. In addition, black pigmented 
colonies were tested for red fluorescence under 
UV light (360 nm) and methanol-negative result 
indicated that colonies were Porphyromonas spp. A. 
actinomycetemcomitans was also primarily identified 
by colony morphology and catalase production.
Using direct method, total cultivable microbiota 
(total microbial load) was count on blood-agar, 
hemin-menadione medium and TSBV medium. The 
percentage of P. gingivalis and T. forsythia was 
obtained using the number of CFU/ml RTF on blood- 
agar hemin- menadione medium as a percentage 
of the total anaerobic count. The percentage of A. 
actinomycetemcomitans was obtained using the 
number of CFU/ml RTF on TSBV as a percentage of 
the total anaerobic counts.
Final identification was made using PCR according 
to Ashimoto protocol.
Outcome variables
The primary outcome variable was change in CAL. 
Secondary outcome variables were changes in PPD, PI 
and BOP, total cultivable microbiota, percentage of P. 
gingivalis, T. forsythia and A. actinomycetemcomitans, 
and prevalence of P. gingivalis, T. forsythia and A. 
actinomycetemcomitans. 
Compliance and adverse reactions
The participant returned the sachets containing 
probiotic or placebo at 1, 2 and 3-month visit. Each 
time, patients received new sachets. Antibiotic group 
participants returned azithromycin tablets at 6-week 
visit. All participants were called by phone each week 
to check for compliance. In each control visit or phone 
call, the clinical examiner (Alicia Morales) inquired the 
participants regarding general health changes, use 
of mouth rinses, use of probiotic products and any 
adverse events.
Statistical analysis
For all statistical assessments, the patient 
was maintained as the unit of measurement. The 
compliance of parameters to the normal distribution 
was assessed using Shapiro Wilk test. The balancing 
of groups by age, sex and smoking was tested by 
Kruskall Wallis, ANOVA and Fisher’s exact tests. 
We recorded quantitative data as the mean value 
± standard deviation or median, measured the 
IQ score by using the Friedman test, and we used 
McNemar test to compare intragroup parameters. 
For both tests, the statistical significance was set at 
p<0.05. We used the Bonferroni- corrected Wilcoxon 
signed ranks test to evaluate intragroup comparisons. 
Bonferroni- corrected Kruskal Wallis, ANOVA and 
Fisher’s exact tests were used to compare intergroup 
parameters. The statistical significance was set at 
p<0.017 for all the Bonferroni- corrected tests.
The statistical analysis was made using a statistical 
package (StataCorp, College Station, TX, U.S.A)
Results
The flow chart of the study is shown in Figure 1. 
Forty-seven patients, 16 in the probiotic group, 16 
in the antibiotic group and 15 in the placebo group 
were analyzed. All patients entering the study also 
completed it. No compliance problems were noted, all 
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patients followed the protocol of the study. Only one 
subject from the antibiotic group reported an adverse 
event (nausea).  
Intergroup analysis
At baseline, no significant differences in 
demographic, medical and clinical characteristics 
were found between groups (p>0.05, Table 1). 
Also, there were no intergroup differences in CAL, 
PPD, BOP, plaque accumulation, total cultivable 
microbiota and percentages of P. gingivalis, A. 
actinomycetemcomitans and T. forsythia at 3, 6, and 
9 months follow-up (Table 2 and 3).
Intragroup analysis
The comparison of CAL, PPD, BOP, plaque 
accumulation values for the baseline and 3-, 6-, and 
9-month time points for all groups are presented 
in Table 2. In the probiotic group we observed a 
significant reduction of the clinical attachment loss at 3 
and 9 months and of the PPD and plaque accumulation 
at all times of the follow-up. In the antibiotic group, we 
perceived a significant reduction of the CAL and BOP 
at 3 and 6 months, as well as a significant reduction 
of the PPD and plaque accumulation at all times of the 
follow-up. Finally, in the placebo group, the CAL, PPD 
and plaque accumulation decreased significantly at all 
times and the BOP at 3 and 6 months. 
Figure 1- Flowchart of the study design
Table 1- Baseline data of patients in the treatment groups
Variable Treatment Group p- value
 Probiotic group (n=16) Antibiotic group (n=16) Placebo group  (n=15)
Age1  (years) 46.5 ± 9.3 49.0 ± 7.9 52.8 ± 7.5 0.1171
Gender (M/F)2 8 / 8 10 / 6 8 / 7 0.8150
Smokers2 7 (43.8%) 3 (18.7%) 6 (40.0%) 0.3440
CAL (mm)3 3.8 ± 0.7 4.4 ± 0.9 4.7 ± 1.5 0.0824
PPD (mm)3 2.7 ± 0.6 2.9 ± 0.4 3.1 ± 0.9 0.2437
BOP (%)1 49.3 ± 18.1 57.4 ± 10.2 52.5 ± 12.6 0.0850
Plaque accumulation (%)3 54.5 ± 18.8 58.6 ± 18.8 56.1 ± 9.4 0.5256
1ANOVA (p<0.05); 2Fisher's exact test (p<0.05); 3Kruskal Wallis test (p<0.05).  
CAL: Clinical attachment level; PPD: Probing pocket depth; BOP: Bleeding on probing.
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Also, we observed a variation of the total cultivable 
microbiota, as seen in Table 2. Compared with baseline, 
there was a significant reduction in the probiotic group 
at 6-month follow-up, while for the antibiotic group it 
occurred at all times (p<0.017). 
In Table 3, we analyzed the variation of the 
microbiological variables between the basal time and 
the 9-month follow-up. Percentage of T. forsythia and 
A. actinomycetemcomitans is not reported, because 
the development of these microorganisms was not 
observed at any time of the analysis. The percentage 
of P. gingivalis (p<0.05) decreased in all the groups, 
compared with baseline. The reduction of the number 
of subjects with P. gingivalis was significant only in 
the placebo group (p<0.05). 
Discussion
This double-blind, placebo-controlled and parallel-
arm randomized clinical trial evaluated clinical 
and microbiological effects of L. rhamnosus SP1 
administered one time a day for 3 months and 
azithromycin, in addition to nonsurgical therapy 
in chronic periodontitis. Our results showed that 
the adjunctive use of L. rhamnosus sachets and 
azithromycin during initial therapy resulted in similar 
periodontal clinical improvements compared with 
mechanical therapy alone. At microbiological level, 
the total cultivable microbiota decreased significantly 
in the probiotic and antibiotic groups. In the placebo 
group, the prevalence of subjects with P. gingivalis 
decreased. However, there were no significant 
differences between groups.
To our knowledge, this is the first study assessing 
and comparing the microbiological impact of the use of 
probiotics and antibiotics on the treatment of chronic 
periodontitis with a 9-month follow-up. In the probiotic 
group, we observed attachment gain, reduction of PPD, 
and reduction of plaque, which was not significant 
when compared with the other groups. This is 
partially consistent with studies using as probiotics: 
Lactobacillus reuteri DSM-17938 + ATCC PTA 528927, 
Streptococcus oralis KJ3 + Streptococcu uberis KJ2 
+ Streptococcu rattus JH14513 and L. rhamnosus 
SP116, but contrary to studies that also used L. reuteri 
strains26,29, as well as Lactobacillus salivarius WB2122, 
in which the probiotic group presented additional 
beneficial effects when compared with the placebo 
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group.
Regarding the use of azithromycin in the treatment 
of chronic periodontitis in our study, a significant 
reduction in all periodontal parameters was observed, 
without intergroup differences, though. This is 
consistent with the studies by Sampaio, et al.20 (2011), 
Han, et al.10 (2012) and Hincapie, et al.12 (2014), 
who concluded that there are no additional effects of 
azithromycin to the nonsurgical periodontal therapy. 
However, some studies show that the antibiotic group 
presents a significant gain of attachment together with 
a significant reduction of BOP and PPD, when compared 
with the placebo group7,14,18,30.
Regarding microbiological parameters, the total 
cultivable microbiota decreased in the probiotic 
group at 6-month follow-up, but without significant 
intergroup differences. This is consistent with the 
studies that used L. reuteri, Streptococcus and 
L. salivarius. Tekce, et al.26 (2015) reported an 
insignificant reduction of the percentage of obligate 
anaerobes at 1-year follow-up in the probiotic group 
(L. reuteri DSM17938 and ATCCPTA5289) and placebo. 
The administration of a probiotic with Streptococcus 
caused a significant reduction of CFU/ml of T. 
forsythia, P. gingivalis, A. actinomycetemcomitans, 
Fusobacterium nucleatum and Prevotella intermedia 
in the probiotic and placebo groups at 3-month 
follow-up, but without significant differences between 
groups13. The intake for 8 weeks of L. salivarius 
WB 21 did not generate significant differences in 
the quantification of A. actinomycetemcomitans, P. 
intermedia, P. gingivalis, T. denticola, and T. forsythia 
in patients with chronic periodontitis, smokers and 
nonsmokers15. In other studies, the evidence is 
contrary. Furthermore, in the study by Teughels, 
et al.27 (2013), samples of subgingival plaque were 
taken at 3, 6, 9 and 12 weeks of intake of probiotic 
L. reuteri DSM17938 and ATCC PTA5289, identifying 
and quantifying in real time by PCR T. forsythia, P. 
gingivalis, A. actinomycetemcomitans, Fusobacterium 
nucleatum and Prevotella intermedia. After 12 weeks 
of treatment with probiotic, a significant reduction 
of the quantification of the periodontopathogens 
selected in both groups was reported. However, in the 
probiotic group, the variation in the colony numbers 
was significantly higher than in the placebo group after 
9 weeks of treatment. In the study by Vivekananda, 
et al.29 (2010), the quadrants of patients who took 
probiotics (L. reuteri DSM-17938 + ATCC PTA 528), 
regardless whether they were treated or not, presented 
a reduction in the number of UFC/ml of P. gingivalis, 
A. actinomycetemcomitans and P. intermedia, at the 
end of the 3-week intake of the probiotic.
In our study, we observed a reduction of the 
total cultivable microbiota at all follow-up times in 
the antibiotic group, but there were no significant 
differences with the other groups. Gomi, et al.7 (2007) 
reported no intergroup differences in the prevalence of 
Table 3- Intra- and intergroup comparisons of microbiological parameters (mean ± SD or median, IQ score at days 0 and 270
Variable Time 
point
Treatment group p- value**
 Probiotic group (n=16) Antibiotic group (n=16) Placebo group  (n=15) For mean For delta
Mean ± SD Delta ± SD Mean ± SD Delta ± SD Mean ± SD Delta ± SD
% P. gingivalis
Day 0 14.2 ± 17.6 -13.1 ± 18.6 17.8 ± 19.3 -15.6 ± 17.9 14.7 ± 15.7 -14.4 ± 15.9 0.97738 0.99028
Day 270 1.1 ± 2.6† 2.1 ± 6.6† 0.3 ± 1.0† 0.5882
Number of subjects with
P. gingivalis
Day 0 15 (93.7%) 14 (87.5%) 13 (86.6%) 0.8590
Day 270 9 (56.2%) 9 (56.3%) 3 (20.0%)† 0.0740
A. actinomycetemcomitans
Day 0 3 (18.7%) 3 (18.7%) 0 (0%) 0.2200
Day 270 1 (6.3%) 6 (37.5%) 5 (33.3%) 0.0860
T. forsythia
Day 0 16 (100%) 16 (100%) 15 (100%) 1.0000
Day 270 12 (75.0%) 11 (68.7%) 10 (66.6%) 0.9240
Intra- group comparison by * Wilcoxon signed rank test and Mc Nemar test. p<0.05. Significant values were given in bold formatting.
Inter- group comparison by ** Kruskal Wallis test, ANOVA and Fisher's exact test. p<0.05
MORALES A, GANDOLFO A, BRAVO J, CARVAJAL P, SILVA N, GODOY C, GARCIA-SESNICH J, HOARE A, DIAZ P, GAMONAL J
J Appl Oral Sci. 2018;26:e201700758/9
P. gingivalis, T. forsythia and A. actinomycetemcomitans 
between the antibiotic and the placebo groups. 
Yashima, et al.30 (2009) reported no significant 
differences between the study groups regarding 
the to ta l  count  o f  bacter ia  a t  12-month 
follow-up and the prevalence of P. gingivalis, 
T. forsythia and A. actinomycetemcomitans. Sampaio, 
et al.20 (2011) reported no significant differences in 
the prevalence and count between the experimental 
and control groups in any periodontopathogen at any 
time of the study. In another trial carried out by Han, 
et al.10 (2012), both groups had a similar percentage 
of periodontopathogens at all the times. There were no 
significant intergroup differences for P. gingivalis, T. 
forsythia and A. actinomycetemcomitans. On the other 
hand, Sefton, et al.21 (1996) reported a significant 
reduction in the total count of microorganisms, black-
pigmented bacteria and P. gingivalis in the antibiotic 
group versus the placebo group. Haffajee, et al.8 
(2008) found a significant difference in the count of 
red-complex bacteria and some species of the orange 
complex for the group treated with azithromycin. Oteo, 
et al.18 (2010) studied the impact of the treatment 
with the mentioned antibiotic in patients with 
chronic periodontitis with presence of P. gingivalis. 
In this experimental group, a significant reduction 
in the frequency of detection of P. gingivalis and A. 
actinomycetemcomitans at 6-month follow-up and of 
T. forsythia at 1-month follow-up were reported. 
However, the identification and quantification of 
the presence of periodontopathogens are not enough, 
since according to the genetic variability of their 
virulence factors, they present resistance to relatively 
high concentrations (200 µg/mL) of Polymyxin B. It is 
a synthetic cationic peptide, used as the gold standard 
of the antimicrobial activity of the endogenous 
cationic peptide, such as the human β defensins2, a 
situation that could be replicated in the case of the 
azithromycin. The microorganism can also present a 
different immunogenicity3. 
The selection of the “best” probiotic for oral health 
is still a controversial topic. In addition to this, evidence 
coming from gastroenterology has started a change in 
the concept of probiotics. The treatment with antibiotic 
destroys the bacterial populations forming the 
commensal microbiota, which generates a dysbiosis, 
increasing the susceptibility to a wide range of other 
bacterial infections, as it reduces the resistance to 
colonization. Specifically, the destruction of obligate 
anaerobes coming from the lower gastrointestinal tract 
results in the expansion of oxygen-tolerant bacteria 
such as γ-proteobacteria and Enterococcus spp. 
This bacterium has been identified in oral diseases, 
including chronic periodontitis, and presents, among 
others, virulence factors associated with resistance 
to antibacterial treatments, becoming a reservoir of 
transferable elements that would favor the genetic 
variability associated with microbial resistance24. 
Hence, it has been proposed that the development of 
commensal bacteria as probiotics is a high priority for 
preventive and therapeutic purposes19. 
The use of antibiotic therapy as an adjunct to the 
treatment of periodontal disease is widely supported 
in the literature, and there is evidence that it 
provides additional beneficial effects to mechanical 
therapy9. However, the optimal usage protocol for 
antibiotic therapy and the clinical effects of the time 
at which antibiotic is administered during the course 
of the periodontal hygienic phase has not yet been 
clearly determined11. According to the literature, 
administration of antibiotics show higher clinical results 
when is accompanied by meticulous disruption and 
mechanical removal of the periodontal biofilm11. In 
our study, the patients started taking the probiotic, 
antibiotic or placebo after the last session of SRP. We 
selected L. rhamnosus as the probiotic for our study 
because it has been shown to have good antimicrobial 
activity against the Gram-negative periodontal 
pathogen25. Mode of administration, dosage and 
frequency may also affect therapy outcomes. In 
our study the L. rhamnosus sachet application 
[(2x107
 
colony forming units (CFU/day)] was started 
immediately after the last session of root planing, one 
time a day for 3 months. Teughels, et al27. (2013) used 
L. reuteri lozenges two times a day for 3 months, 1x108
 
CFU/day, immediately after a full-mouth disinfection 
procedure.
The major limitation of our study is the statistical 
power. This study could be too small to detect the real 
differences between the groups. An increase of the 
sample size is suggested.
In conclusion, the administration of L. rhamnosus 
SP1 in sachets and azithromycin in pills for the 
treatment of chronic periodontitis generates clinical 
and microbiological effects similar to the SRP on its 
own. 
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J Appl Oral Sci. 2018;26:e201700759/9
Acknowledgments
This study was supported by a grant provided by 
the Scientific and Technologic Investigation Resource, 
Santiago, Chile (Fondecyt Project no. 1130570) and 
CONICYT-PCHA/Magíster Nacional/2013 –130172. We 
would like to thank Mr. Juan Fernandez from Language 
and Translation services of the Faculty of Dentistry, 
University of Chile for kindly correcting the English 
spelling and grammar of this study. The authors 
declare that there are no conflicts of interest.
References
1- Aas JA, Paster BJ, Stokes LN, Olsen I, Dewhirst FE. Defining 
the normal bacterial flora of the oral cavity. J Clin Microbiol. 
2005;43(11):5721-32.
2- Coats SR, To TT, Jain S, Braham PH, Darveau RP. Porphyromonas 
gingivalis resistance to polymyxin B is determined by the lipid A 
4’-phosphatase, PGN_0524. Int J Oral Sci. 2009;1(3):126-35.
3- Díaz-Zúñiga J, Yáñez-Figueroa J, Melgar-Rodríguez S, Álvarez-Rivas 
C, Rojas-Lagos L, Vernal-Astudillo R. Virulence and variability on 
Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans 
and their association to periodontitis. Rev Clin Periodoncia Implantol 
Rehabil Oral. 2012;5(1):40-5.
4- Drisko CH. Nonsurgical periodontal therapies. Periodontol 2000. 
2001;25:77-88.
5- Gajardo M, Silva N, Gomez L, Leon R, Parra B, Contreras A, et al. 
Prevalence of periodontopathic bacteria in aggressive periodontitis 
patients in a Chilean population. J Periodontol. 2005;76(2):289-94.
6- Gamonal J, Mendoza C, Espinoza I, Munoz A, Urzua I, Aranda W, et 
al. Clinical attachment loss in Chilean adult population: first Chilean 
national dental examination survey. J Periodontol. 2010;81(10):1403-
10.
7- Gomi K, Yashima A, Iino F, Kanazashi M, Nagano T, Shibukawa N, et 
al. Drug concentration in inflamed periodontal tissues after systemically 
administered azithromycin. J Periodontol. 2007;78(5):918-23.
8- Haffajee AD, Socransky SS, Patel MR, Song X. Microbial complexes 
in supragingival plaque. Oral Microbiol Immunol. 2008;23(3):196-205.
9- Haffajee AD, Socransky SS, Gunsolley JC. Systemic anti-
infective periodontal therapy. A systematic review. Ann Periodontol. 
2003;8(1):115-81.
10- Han B, Emingil G, Ozdemir G, Tervahartiala T, Vural C, Atilla G, et al. 
Azithromycin as an adjunctive treatment of generalized severe chronic 
periodontitis: clinical, microbiologic, and biochemical parameters. J 
Periodontol. 2012;83(12):1480-91.
11- Herrera D, Alonso B, Leon R, Roldan S, Sanz M. Antimicrobial 
therapy in periodontitis: the use of systemic antimicrobials against 
the subgingival biofilm. J Clin Periodontol. 2008;35(8 Suppl):45-66.
12- Hincapie JP, Castrillon CA, Yepes FL, Roldan N, Becerra MA, 
Moreno SM, et al. Microbiological effects of periodontal therapy plus 
azithromycin in patients with diabetes: results from a randomized 
clinical trial. Acta Odontol Latinoam. 2014;27(2):89-95.
13- Laleman I, Yilmaz E, Ozcelik O, Haytac C, Pauwels M, Herrero 
ER, et al. The effect of a streptococci containing probiotic in 
periodontal therapy: a randomized controlled trial. J Clin Periodontol. 
2015;42(11):1032-41.
14- Martande SS, Pradeep AR, Singh SP, Kumari M, Naik SB, Suke 
DK, et al. Clinical and microbiological effects of systemic azithromycin 
in adjunct to nonsurgical periodontal therapy in treatment of 
Aggregatibacter actinomycetemcomitans associated periodontitis: 
a randomized placebo-controlled clinical trial. J Investig Clin Dent. 
2016;7(1):72-80.
15- Mayanagi G, Kimura M, Nakaya S, Hirata H, Sakamoto M, Benno 
Y, et al. Probiotic effects of orally administered Lactobacillus salivarius 
WB21-containing tablets on periodontopathic bacteria: a double-
blinded, placebo-controlled, randomized clinical trial. J Clin Periodontol. 
2009;36(6):506-13.
16- Morales A, Carvajal P, Silva N, Hernandez M, Godoy C, Rodriguez 
G, et al. Clinical effects of Lactobacillus rhamnosus in non-surgical 
treatment of chronic periodontitis: a randomized placebo-controlled 
trial with 1-year follow-up. J Periodontol. 2016;87(8):944-52.
17- Muniz FW, Oliveira CC, Carvalho RS, Moreira MM, Moraes ME, 
Martins RS. Azithromycin: a new concept in adjuvant treatment of 
periodontitis. Eur J Pharmacol. 2013;705(1-3):135-9.
18- Oteo A, Herrera D, Figuero E, O’Connor A, Gonzalez I, Sanz M. 
Azithromycin as an adjunct to scaling and root planing in the treatment 
of Porphyromonas gingivalis-associated periodontitis: a pilot study. J 
Clin Periodontol. 2010;37(11):1005-15.
19- Pamer EG. Resurrecting the intestinal microbiota to combat 
antibiotic-resistant pathogens. Science. 2016;352(6285):535-8.
20- Sampaio E, Rocha M, Figueiredo LC, Faveri M, Duarte PM, Gomes 
Lira EA, et al. Clinical and microbiological effects of azithromycin in the 
treatment of generalized chronic periodontitis: a randomized placebo-
controlled clinical trial. J Clin Periodontol. 2011;38(9):838-46.
21- Sefton AM, Maskell JP, Beighton D, Whiley A, Shain H, Foyle D, 
et al. Azithromycin in the treatment of periodontal disease: effect on 
microbial flora. J Clin Periodontol. 1996;23(11):998-1003.
22- Shimauchi H, Mayanagi G, Nakaya S, Minamibuchi M, Ito Y, Yamaki 
K, et al. Improvement of periodontal condition by probiotics with 
Lactobacillus salivarius WB21: a randomized, double-blind, placebo-
controlled study. J Clin Periodontol. 2008;35(10):897-905.
23- Socransky SS, Haffajee AD, Cugini MA, Smith C, Kent RL Jr. 
Microbial complexes in subgingival plaque. J Clin Periodontol. 
1998;25(2):134-44.
24- Sun J, Sundsfjord A, Song X. Enterococcus faecalis from patients 
with chronic periodontitis: virulence and antimicrobial resistance traits 
and determinants. Eur J Clin Microbiol Infect Dis. 2012;31(3):267-72.
25- Teanpaisan R, Piwat S, Dahlen G. Inhibitory effect of oral Lactobacillus 
against oral pathogens. Lett Appl Microbiol. 2011;53(4):452-9.
26- Tekce M, Ince G, Gursoy H, Dirikan Ipci S, Cakar G, Kadir T, et al. 
Clinical and microbiological effects of probiotic lozenges in the treatment 
of chronic periodontitis: a 1-year follow-up study. J Clin Periodontol. 
2015;42(4):363-72.
27- Teughels W, Durukan A, Ozcelik O, Pauwels M, Quirynen M, 
Haytac MC. Clinical and microbiological effects of Lactobacillus reuteri 
probiotics in the treatment of chronic periodontitis: a randomized 
placebo-controlled study. J Clin Periodontol. 2013;40(11):1025-35.
28- Van der Velden U. Purpose and problems of periodontal disease 
classification. Periodontol 2000. 2005;39:13-21
29- Vivekananda MR, Vandana KL, Bhat KG. Effect of the probiotic 
Lactobacilli reuteri (Prodentis) in the management of periodontal 
disease: a preliminary randomized clinical trial. J Oral Microbiol. 
2010;2:10.3402/jom.v2i0.5344.
30- Yashima A, Gomi K, Maeda N, Arai T. One-stage full-mouth 
versus partial-mouth scaling and root planing during the effective 
half-life of systemically administered azithromycin. J Periodontol. 
2009;80(9):1406-13.
MORALES A, GANDOLFO A, BRAVO J, CARVAJAL P, SILVA N, GODOY C, GARCIA-SESNICH J, HOARE A, DIAZ P, GAMONAL J
